CERES BRAIN Therapeutics a republié ceci
Good news never comes alone! Ceres lead compound, CBT101, has now received all the necessary approvals to enter a Phase 1 clinical trial. Following our latest funding round of 6M€, we are thrilled to announce that the French regulatory authorities (ANSM) and the Ethical Review Committee (CPP) have approved the launch of the first Phase 1 clinical trial for CBT101 in healthy volunteers. This trial will be conducted at the Eurofins/Optimed facilities in Grenoble, France. This marks a significant milestone in the development of CBT101, bringing us closer to our goal of providing a new therapeutic option for patients suffering from neurometabolic diseases. A huge thank you to all the teams and partners who made this achievement possible!